NTRA
Natera
October 22, 2026 · intraday
- Rarity
- 1.16
- Peak move
- −6.62%
- Float cap
- $53.9B
Still running — rarity and peak move can only rise from here.
Natera is a molecular diagnostics company that sells cell-free DNA testing services across three areas: oncology, women's health, and organ health. Its products include the Signatera test for detecting residual cancer and monitoring recurrence, the Panorama non-invasive prenatal screen and Horizon carrier screening, and Prospera for assessing organ transplant rejection. It sells primarily to physicians, hospitals, and laboratories in the United States, with some prenatal testing in Europe.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.